Oncology · AKT InhibitorRegulatory Approvalregulatorymid-term

FDA Acceptance of NDA for Capivasertib by AstraZeneca

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/18/2026, 12:31:43 PM

Assessment confidence: 90% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's acceptance of the NDA for Capivasertib is a significant milestone for AstraZeneca, indicating potential market entry in the oncology sector. This development necessitates strategic planning to address competitive dynamics in the AKT inhibitor space. Regulatory context from FDA (FDA AP — TRUQAP (SUPPL)) supports the near-term read. Assessment grounded in 25 ranked evidence items (25 high-relevance).

Strategic Assessment

Portfolio teams should prepare for potential market entry strategies and assess competitive positioning against existing therapies. The strongest clinical anchor is Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o (ClinicalTrials.gov), entity match (capivasertib). In Oncology · AKT Inhibitor, 5 regulatory and 4 competitive items passed relevance filtering for AstraZeneca.

Competitive Pressure

The most relevant competitive pressure comes from FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer (Humanexa Signals) — entity match (oncology). Secondary pressure from Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer. This acceptance positions AstraZeneca to potentially compete in the oncology space with other AKT inhibitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — TRUQAP (SUPPL) (FDA). Entity match (astrazeneca); Regulatory pathway relevance (nda). The acceptance of the NDA signifies a critical step in the regulatory process, with implications for future approval timelines and market readiness.

Key Risks

Elevated medium regulatory exposure for AstraZeneca could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not) could weigh on AstraZeneca through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The approval could enhance AstraZeneca's market share in oncology, particularly against other AKT inhibitors, impacting revenue streams and competitive positioning.
Upside for AstraZeneca may improve if Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o (ClinicalTrials.gov) delivers favorable follow-through.
Upside for AstraZeneca may improve if Dectin-1 signaling promotes Galectin-3 shedding and expansion of immunosuppressive CD71+ erythroid cells in breast cancer. (PubMed) delivers favorable follow-through.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Oncology · Breast Cancer · Regulatory Approval · Giredestrant is positioned to potentially become the new standard-of-care in adjuvant treatment for early-stage ER-positive breast cancer, a significant advancement in over 20 years.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for the FDA's decision and any subsequent announcements regarding Capivasertib's clinical data.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — TRUQAP (SUPPL)
FDAhigh relevance
Entity match (astrazeneca); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BAXFENDY (ORIG)
FDAhigh relevance
Entity match (astrazeneca); Regulatory pathway relevance (nda)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Entity match (oncology)
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase o
ClinicalTrials.govhigh relevance
Entity match (capivasertib)
FDA document
View source
The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govhigh relevance
Entity match (oncology)
FDA document
View source
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
ClinicalTrials.govhigh relevance
Entity match (oncology)
FDA document
View source
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
ClinicalTrials.govhigh relevance
Entity match (capivasertib)
FDA document
View source
Toxicity of Treatments for Non-tuberculous Mycobacterial Infections in Cancer Patients or Not
ClinicalTrials.govhigh relevance
Entity match (cancer patients)
FDA document
View source
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Cachexia and Gut Microbiota in Patients With Breast Cancer Receiving Home Care
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

FDA ODAC Recommends Truqap for PTEN-Deficient Prostate Cancer
Humanexa Signalshigh relevance
Entity match (oncology)
Datroway approved in US as first TROP2-directed ADC for 1L triple-negative breast cancer
Humanexa Signalshigh relevance
Entity match (oncology)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Entity match (oncology)
FDA Accepts NDA for Roche's Giredestrant in Early-Stage ER-Positive Breast Cancer
Humanexa Signalshigh relevance
Entity match (oncology)

Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedhigh relevance
Entity match (oncology)
FDA document
View source
UBE2C promotes pancreatic cancer progression through PI3K/Akt/mTOR signaling pathway.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedhigh relevance
Entity match (oncology)
FDA document
View source
Genetic variants of the transporter SLC22A4 affect the abundance and survival of Fusobacterium nucleatum in colorectal cancer.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Dectin-1 signaling promotes Galectin-3 shedding and expansion of immunosuppressive CD71+ erythroid cells in breast cancer.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
A qualitative study exploring discharge readiness experiences among patients with esophageal cancer undergoing esophagectomy.
PubMedhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

AstraZeneca
Capivasertib
cancer patients
Oncology

Commercial impact

medium

The approval could enhance AstraZeneca's market share in oncology, particularly against other AKT inhibitors, impacting revenue streams and competitive positioning.

Regulatory impact

medium

The acceptance of the NDA signifies a critical step in the regulatory process, with implications for future approval timelines and market readiness.

What to watch

Monitor the timeline for the FDA's decision and any subsequent announcements regarding Capivasertib's clinical data.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.